Cipla's generic version of Seretide has finally received regulatory approval in the UK, bringing much needed relief to investors and opening up more competition for GlaxoSmithKline on its home turf.
Cipla Ltd. has received final approval from the UK MHRA for its fluticasone + salmeterol metered dose inhaler (Sereflo), ending several months of investor anxiety over the product’s debut on the British market. (Also see "Operational Fixes At Cipla But All Eyes On Generic Advair" - Scrip, 25 May, 2016.)
Cipla said that its Sereflo 25mcg/125mcg and 25mcg/250mcg are generic “equivalent” versions to GlaxoSmithKline PLC’s Seretide Inhalers for asthma....
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
